ADC Combination Therapy for Lymphoma

1. ADC Combination Therapy for Lymphoma www.creative-biolabs.com/adc

2. Background Lymphoma is a cancer that develops in the lymphatic system and is mainly divided into two types of Hodgkin's lymphoma and non-Hodgkin's lymphoma. And there are large, abnormal lymphocytes, Reed-Sternberg cells, in their lymph nodes of most patients with Hodgkin's lymphoma. As long as the intervention is early enough, these patients can often achieve long-term relief.

3. ADC Combination Therapy Recently, the FDA announced the approval of the antibody drug conjugate of Seattle Genetics, Adcetris (brentuximab vedotin), to expand indications and use it together with chemotherapy to treat patients with classic stage III or IV classical Hodgkin's lymphoma. The approved Adcetris is such a new drug that is expected to bring a gospel to lymphoma patients. As an antibody drug conjugate, it is composed of an antibody brentuximab that targets the CD30 antigen and an anti-mitotic drug monomethyl astasemidine E (MMAE). The CD30 protein is a known molecular marker of classical Hodgkin's lymphoma, and MMAE can effectively block cell mitosis by inhibiting the polymerization of tubulin, which consists of the conjugated protease-cleavable agent of Seattle Genetics. Adcetris can stably exist in the blood circulation. When it is internalized by CD30+ tumor cells, it can release MMAE, leading to cell death.

4. The clinical trial In a clinical trial, the potential of Adcetris to treat classical Hodgkin's lymphoma was verified - the researchers recruited 1,334 treated patients who had previously received an average of 6 cycles of 28 days. Subsequently, they were divided into two groups, one group receiving Adcetris and chemotherapy (AVD), and the other group receiving only chemotherapy (ABVD). Studies have shown that compared with patients who receive only chemotherapy, patients who receive combination therapy experience a 23% reduction in disease progression, death, or the need to start new treatments. In combination with G-CSF (a growth factor that promotes bone marrow leukocyte growth), the combination of Adcetris and chemotherapy is recommended by the FDA for first-line treatment of stage III or IV classical Hodgkin's lymphoma. In response to this indication, Adcetris was also qualified for breakthrough therapy and prioritized review.

5. Established in 2004, Creative Biolabs is highly specialized in advanced antibody biochemistry and engineering. With more than a decade of exploration and expansion, our current research and service capacity covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, we have established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with our customers and research partners to develop new medicines for a better, healthier world. After years of pursuit for perfection, Creative Biolabs has established our leadership in targeted immunotherapy and ADC development. Creative Biolabs

6. As a global company, we have more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, we are the established leading expert in TCR and CAR T&NK cell immune therapy development, as we offer the one-stop custom services that cover the entire new drug development pipeline. Creative Biolabs

7. Contact Us 45-1 Ramsey Road, Shirley, NY 11967, USA Email: marketing@creative-biolabs.com

8. Thanks